| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | CAIRN BIOSCIENCES, INC. | 455 MISSION BAY BLVD SOUTH, SUITE 145 | SAN FRANCISCO | CA | 94158-2159 | SAN FRANCISCO | USA | R44DA048686 | High-throughput profiling of compound abuse liabilities and identification of addiction-related drug targets using an iPSC-enabled platform | 000 | 1 | NIH | 10/22/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = -$3 ) |
| | 2021 | 2019 | CAIRN BIOSCIENCES, INC. | 455 MISSION BAY BLVD SOUTH, SUITE 145 | SAN FRANCISCO | CA | 94158-2159 | SAN FRANCISCO | USA | R44TR002572 | Multiplexed high-content assay for toxicity profiling using live iPSC-derived cardiomyocyte lines with lineage-specific barcoding | 000 | 3 | NIH | 5/29/2021 | -$3 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | CAIRN BIOSCIENCES, INC. | 455 MISSION BAY BLVD SOUTH, SUITE 145 | SAN FRANCISCO | CA | 94158-2159 | SAN FRANCISCO | USA | R44DA048686 | High-throughput profiling of compound abuse liabilities and identification of addiction-related drug targets using an iPSC-enabled platform | 000 | 1 | NIH | 4/30/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,145,309 ) |
| | 2019 | 2019 | CAIRN BIOSCIENCES, INC. | 455 MISSION BAY BLVD SOUTH, SUITE 145 | SAN FRANCISCO | CA | 94158-2159 | SAN FRANCISCO | USA | R44TR002572 | Multiplexed high-content assay for toxicity profiling using live iPSC-derived cardiomyocyte lines with lineage-specific barcoding | 001 | 3 | NIH | 8/7/2019 | $821,559 |
| | 2019 | 2019 | CAIRN BIOSCIENCES, INC. | 455 MISSION BAY BLVD SOUTH, SUITE 145 | SAN FRANCISCO | CA | 94158-2159 | SAN FRANCISCO | USA | R44DA048686 | High-throughput profiling of compound abuse liabilities and identification of addiction-related drug targets using an iPSC-enabled platform | 000 | 1 | NIH | 9/13/2019 | $323,750 |
| | 2019 | 2018 | CAIRN BIOSCIENCES, INC. | 455 MISSION BAY BLVD SOUTH, SUITE 145 | SAN FRANCISCO | CA | 94158-2159 | SAN FRANCISCO | USA | R44TR002572 | Multiplexed high-content assay for toxicity profiling using live iPSC-derived cardiomyocyte lines with lineage-specific barcoding | 000 | 2 | NIH | 8/1/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,178,386 ) |
| | 2018 | 2018 | CAIRN BIOSCIENCES, INC. | 455 MISSION BAY BLVD SOUTH, SUITE 145 | SAN FRANCISCO | CA | 94158-2159 | SAN FRANCISCO | USA | R44TR002572 | Multiplexed high-content assay for toxicity profiling using live iPSC-derived cardiomyocyte lines with lineage-specific barcoding | 000 | 2 | NIH | 8/9/2018 | $1,178,386 |
|
|
